Editorial: paradoxical skin lesions during anti-TNF treatment—an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors’ reply

Han Hee Lee; Jung Min Bae; Bo In Lee

doi:10.1111/apt.14917

Editorial: paradoxical skin lesions during anti-TNF treatment—an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors’ reply

Han Hee Lee
, Jung Min Bae
, Bo In Lee

The Catholic University of Korea

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	684-685
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	48
Issue number	6
DOIs	https://doi.org/10.1111/apt.14917
State	Published - Sep 2018

Access to Document

10.1111/apt.14917

Cite this

@article{abb1ff9ea4c34d41b9b31a9f6f4162d9,

title = "Editorial: paradoxical skin lesions during anti-TNF treatment—an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors{\textquoteright} reply",

author = "Lee, \{Han Hee\} and Bae, \{Jung Min\} and Lee, \{Bo In\}",

year = "2018",

month = sep,

doi = "10.1111/apt.14917",

language = "English",

volume = "48",

pages = "684--685",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Editorial

T2 - paradoxical skin lesions during anti-TNF treatment—an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors’ reply

AU - Lee, Han Hee

AU - Bae, Jung Min

AU - Lee, Bo In

PY - 2018/9

Y1 - 2018/9

UR - https://www.scopus.com/pages/publications/85051849473

U2 - 10.1111/apt.14917

DO - 10.1111/apt.14917

M3 - Editorial

C2 - 30132943

AN - SCOPUS:85051849473

SN - 0269-2813

VL - 48

SP - 684

EP - 685

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 6

ER -

Editorial: paradoxical skin lesions during anti-TNF treatment—an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors’ reply

Access to Document

Other files and links

Cite this